Skip to main content

Table 5 Percent changes in median (mean) antibody levels in sera and corresponding IC during 24-month follow-up

From: Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus

 0–3 months0–6 months0–12 months0–24 months
 SerumICSerumICSerumICSerumIC
AntibodyChangepChangepChangepChangepChangepChangepChangepChangep
dsDNA− 21.4< 0.001− 18.20.008− 34.4< 0.001− 25.00.049− 32.3< 0.001− 40.30.044− 34.90.022− 36.40.002
(− 17.2)n = 41(− 6.6)n = 41(− 27.1)n = 35(6.2)n = 35(62.7)n = 30(1.7)n = 30(− 24.8)n = 22(− 28.2)n = 21
Histone− 23.1< 0.00100.414− 26.1< 0.00100.687−24.80.1051−17.90.595−23.60.411− 13.90.015
(− 17.2)n = 41(95.4)n = 41(5.5)n = 35(15.6)n = 34(64.9)n = 30(23.3)n = 29(4.4)n = 22(− 6.5)n = 21
Ribosomal P− 20.0< 0.00100.993− 31.2< 0.0013.330.841− 36.5< 0.001− 26.90.105− 41.80.001− 15.90.933
(− 13.6)n = 41(49.5)n = 38(− 32.4)n = 35(25.2)n = 32(− 28.7)n = 30(1.9)n = 28(− 30.8)n = 22(40.6)n = 21
PCNA−26.0< 0.001−11.20.091−31.5< 0.0012.60.773−30.2< 0.0012.20.442−36.1< 0.001−31.10.006
(− 19.0)n = 41(− 3.0)n = 41(− 24.6)n = 35(22.3)n = 35(− 10.3)n = 30(15.1)n = 30(− 35.6)n = 22(− 17.3)n = 21
SSA/Ro60− 2.80.034− 1.40.222− 7.10.0115− 7.10.599− 7.00.048− 21.70.211− 6.10.0575− 33.00.007
(− 8.6)n = 41(1.3)n = 41(− 9.3)n = 35(30.2)n = 35(10.2)n = 30(8.1)n = 30(28.9)n = 22(− 6.5)n = 21
SSB/La− 11.9< 0.001− 14.30.274− 14.90.008− 7.70.053− 24.90.008− 20.80.051− 27.70.041− 14.20.143
(− 11.0)n = 41(9.0)n = 41(− 13.1)n = 35(16.3)n = 35(54.2)n = 30(9.4)n = 30(− 23.7)n = 22(23.0)n = 21
SSA/Ro52− 9.30.1787− 14.30.124− 6.80.474− 3.50.315− 3.80.078− 15.50.292− 10.6< 0.001− 28.20.005
(− 6.8)n = 41(− 4.7)n = 41(− 7.7)n = 35(22.7)n = 35(− 6.7)n = 30(8.9)n = 30(− 20.4)n = 22(− 11.8)n = 21
Sm− 25.0< 0.00100.406− 16.70.00500.813− 12.80.228− 27.30.292− 30.00.0532− 40.90.050
(− 24.6)n = 41(0.1)n = 33(− 18.0)n = 35(2.0)n = 31(17.7)n = 30(− 12.0)n = 28(− 1.5)n = 22(− 26.6)n = 18
U1RNP− 13.80.0001− 12.50.111− 13.30.010− 16.70.167− 12.30.006− 26.60.001− 22.8< 0.001− 26.3< 0.001
(− 4.4)n = 41(4.4)n = 41(3.4)n = 35(2.2)n = 35(17.5)n = 30(3.8)n = 30(− 19.3)n = 22(− 24.4)n = 21
Sm-U1RNP− 14.7< 0.00100.621− 15.2< 0.001− 14.30.137− 22.40.009− 33.20.019− 31.5< 0.001− 25.00.007
(− 17.4)n = 41(7.4)n = 40(− 15.7)n = 35(0.8)n = 34(11.1)n = 30(4.9)n = 30(− 25.5)n = 22(− 9.2)n = 21
  1. Differences were compared pairwise with the Wilcoxon signed rank test. Negative values indicate decreasing antibody levels; significant changes are presented in italics. The number of SLE-samples in the individual pairwise comparisons is stated below the p values